NCT00306527View on ClinicalTrials.gov

Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

2,235

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

April 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Cell culture derived influenza vaccine

as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm

BIOLOGICAL

egg-derived influenza subunit vaccine

as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm

Trial Locations (5)

25-381

Wojewódzki Szpital Dzieci_cy, Ul. Langiewicza 2

30-969

Centrum Bada_ Farmakologii Klinicznej, Ul. Ujastek 3

31-832

NZOZ Jagiello_skie, Centrum Medyczne Sp. Z O.o., O_. Jagiello_skie 1

31-115

"NZOZ Praktyka Grupowa Lekarzy Rodzinnych, Familia Sp. z o.o.", Pl. Sikorskiego 6a

31-202

Szpital Jana Pawła II, Oddz. Neuroinfekcji, Ul. Pr_dnicka 80

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines and Diagnostics S.r.l.

UNKNOWN

lead

Novartis Vaccines

INDUSTRY

NCT00306527 - Comparison of Safety, Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly | Biotech Hunter | Biotech Hunter